

: CJPNOPV178763

: 11-10-2023 11:30

OP Visit No

Reported on

Specimen

Age/Gender **Patient Name** : Mrs. SHOBA RANI S : 51 Y/F

UHID/MR No.

: CJPN.0000088585

Sample Collected on :

LRN#

: RAD2122296

Ref Doctor Emp/Auth/TPA ID

: SELF

: 9535046667

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Normal in size and echotexture. No focal lesion seen.

No intra hepatic biliary / venous radicular dilation.

CBD and Main Portal vein appear normal.PV-10 mm.

GALL BLADDER: Well distended. Normal in internal contents. Wall Thickness is normal.

SPLEEN: Normal in size and echotexture. No focal lesion was seen.

PANCREAS: Appeared normal to the visualized extent.

KIDNEYS: Both kidneys are normal in size, shape and outlines Cortico medullary delineation is normal. No Hydronephrosis / No calculi.

Right kidney measures:11.7 x 2.0 cm.

Left kidney measures :11.8 x 2.0 cm.

URINARY BLADDER: Well distended. Normal in internal contents. Wall thickness is normal.

UTERUS: Normal in size and echotexture. It measures: 7.0 x 3.0 x 3.4 cm. Uniform myometrial echoes are normal. Endometrial thickness measuring- 3 mm.

No focal lesion was noted.

OVARIES: Both ovaries are normal in size.

Right ovary measures: 2.8 x 2.0 cm. Left ovary measures :2.9 x 2.2 cm.

No free fluid is seen in the peritoneum. No lymphadenopathy.



Patient Name : Mrs. SHOBA RANI S Age/Gender : 51 Y/F

IMPRESSION: NORMAL STUDY.

Please Note: No preparation done before scanning.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

 $\frac{\text{Dr. KUSUMA JAYARAM}}{\text{MBBS,DMRD}}$ Radiology





Patient Name : Mrs.SHOBA RANI S Age/Gender : 51 Y 6 M 26 D/F

UHID/MR No : CJPN.0000088585 Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM
Received : 11/Oct/2023 12:48PM
Reported : 11/Oct/2023 04:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEI	EL - FULL BODY HC	STARTER FEM	IALE - PAN INDIA - FY2	324	
Test Name	Result	Unit	Bio. Ref. Range	Method	1

HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.7	g/dL	12-15	Spectrophotometer
PCV	40.60	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.79	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	84.8	fL	83-101	Calculated
MCH	28.6	pg	27-32	Calculated
MCHC	33.8	g/dL	31.5-34.5	Calculated
R.D.W	14.4	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,250	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (I	DLC)			
NEUTROPHILS	58.2	%	40-80	Electrical Impedance
LYMPHOCYTES	29.3	%	20-40	Electrical Impedance
EOSINOPHILS	6.7	%	1-6	Electrical Impedance
MONOCYTES	5.5	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4801.5	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2417.25	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	552.75	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	453.75	Cells/cu.mm	200-1000	Electrical Impedance
BASOPHILS	24.75	Cells/cu.mm	0-100	Electrical Impedance
PLATELET COUNT	279000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	43	mm at the end of 1 hour	0-20	Modified Westegren method
PERIPHERAL SMEAR				

RBCs: are normocytic normochromic

WBCs: are normal in total number with increase in eosinophils.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Page 1 of 13









: Mrs.SHOBA RANI S

Age/Gender

: 51 Y 6 M 26 D/F

UHID/MR No

: CJPN.0000088585

Visit ID

: CJPNOPV178763

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9535046667 Collected

: 11/Oct/2023 08:36AM

Received

: 11/Oct/2023 12:48PM : 11/Oct/2023 04:43PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE WITH EOSINOPHILIA.

Page 2 of 13



SIN No:BED230248755

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







Age/Gender : 51 Y 6 M 26 D/F
UHID/MR No : CJPN.0000088585

Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM

Received : 11/Oct/2023 12:48PM Reported : 11/Oct/2023 05:53PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEI	EL - FULL BODY HC	STARTER FEM	ALE - PAN INDIA - FY2	324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTO	OR , WHOLE BLOOD EDTA	5 5 5 1 6
BLOOD GROUP TYPE	0	Microplate Hemagglutination
Rh TYPE	Positive	Microplate Hemagglutination

Page 3 of 13

SIN No:BED230248755

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







Age/Gender : 51 Y 6 M 26 D/F

UHID/MR No : CJPN.0000088585

Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM

Received : 11/Oct/2023 01:12PM Reported : 11/Oct/2023 06:14PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

IGLUCUSE, FASTING, NAF PLASMA 137 mg/dL 70-100 HEXOKINAS	SLUCOSE, FASTING , NAF PLASMA	137	mg/dL	70-100	HEXOKINASE
--	-------------------------------	-----	-------	--------	------------

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

HBA1C, GLYCATED HEMOGLOBIN,	7.1	%	HPLC
WHOLE BLOOD EDTA			
ESTIMATED AVERAGE GLUCOSE (eAG),	157	mg/dL	Calculated
WHOLE BLOOD EDTA			

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.

Page 4 of 13







Age/Gender : 51 Y 6 M 26 D/F

UHID/MR No : CJPN.0000088585

Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM

Received : 11/Oct/2023 01:12PM Reported : 11/Oct/2023 06:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 13



SIN No:PLF02039278,EDT230093634 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Age/Gender : 51 Y 6 M 26 D/F
UHID/MR No : CJPN.0000088585

Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM

Received : 11/Oct/2023 12:35PM Reported : 11/Oct/2023 04:01PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEI	EL - FULL BODY HC	STARTER FEM	IALE - PAN INDIA - FY2	324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	167	mg/dL	<200	CHO-POD
TRIGLYCERIDES	98	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	34	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	133	mg/dL	<130	Calculated
LDL CHOLESTEROL	113.2	mg/dL	<100	Calculated
VLDL CHOLESTEROL	19.6	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.91		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .I D1 .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 13

SIN No:SE04508365

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Aduress: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034





Age/Gender : 51 Y 6 M 26 D/F

UHID/MR No : CJPN.0000088585

Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM

Received : 11/Oct/2023 12:35PM Reported : 11/Oct/2023 04:01PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHER	ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324								
Test Name	Result	Unit	Bio. Ref. Range	Method					

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.41	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.09	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.32	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	17	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	21.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	122.00	U/L	30-120	IFCC
PROTEIN, TOTAL	6.89	g/dL	6.6-8.3	Biuret
ALBUMIN	3.70	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.19	g/dL	2.0-3.5	Calculated
A/G RATIO	1.16		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 13







: Mrs.SHOBA RANI S

Age/Gender

: 51 Y 6 M 26 D/F

UHID/MR No Visit ID

: CJPN.0000088585

Ref Doctor

: CJPNOPV178763

: Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected

: 11/Oct/2023 08:36AM

Received

: 11/Oct/2023 12:35PM : 11/Oct/2023 04:01PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

Page 8 of 13



SIN No:SE04508365

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Adultess: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mrs.SHOBA RANI S

Age/Gender

: 51 Y 6 M 26 D/F

UHID/MR No

: CJPN.0000088585

Visit ID Ref Doctor : CJPNOPV178763

Emp/Auth/TPA ID

: Dr.SELF : 9535046667 Collected

: 11/Oct/2023 08:36AM

Received

: 11/Oct/2023 12:35PM

Reported

: 11/Oct/2023 04:01PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEI	ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324								
Test Name	Result	Unit	Bio. Ref. Range	Method					

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM							
CREATININE	0.70	mg/dL	0.72 – 1.18	JAFFE METHOD			
UREA	20.60	mg/dL	17-43	GLDH, Kinetic Assay			
BLOOD UREA NITROGEN	9.6	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	6.00	mg/dL	2.6-6.0	Uricase PAP			
CALCIUM	8.50	mg/dL	8.8-10.6	Arsenazo III			
PHOSPHORUS, INORGANIC	3.60	mg/dL	2.5-4.5	Phosphomolybdate Complex			
SODIUM	140	mmol/L	136–146	ISE (Indirect)			
POTASSIUM	4.6	mmol/L	3.5–5.1	ISE (Indirect)			
CHLORIDE	107	mmol/L	101–109	ISE (Indirect)			

Page 9 of 13



SIN No:SE04508365

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







: Mrs.SHOBA RANI S

Age/Gender

: 51 Y 6 M 26 D/F

UHID/MR No

: CJPN.0000088585

Visit ID

: CJPNOPV178763

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 9535046667

Collected

: 11/Oct/2023 08:36AM

Received

: 11/Oct/2023 12:35PM : 11/Oct/2023 04:01PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	18.00	U/L	<38	IFCC	
(GGT) , SERUM			_		

Page 10 of 13

SIN No:SE04508365

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Adultess: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







Age/Gender : 51 Y 6 M 26 D/F UHID/MR No : CJPN.0000088585

Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:36AM

Received : 11/Oct/2023 09:18PM Reported : 11/Oct/2023 10:50PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEE	EL - FULL BODY HC	STARTER FEM	IALE - PAN INDIA - FY2	324
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM							
TRI-IODOTHYRONINE (T3, TOTAL) 1.3 ng/mL 0.7-2.04 CLIA							
THYROXINE (T4, TOTAL)	14.40	μg/dL	5.48-14.28	CLIA			
THYROID STIMULATING HORMONE (TSH)	1.580	μIU/mL	0.35-4.94	CMIA			

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 13

SIN No:SPL23145205

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK

Aduress: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







Patient Name : Mrs.SHOBA RANI S Age/Gender : 51 Y 6 M 26 D/F

UHID/MR No : CJPN.0000088585 Visit ID : CJPNOPV178763

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9535046667 Collected : 11/Oct/2023 08:31AM
Received : 11/Oct/2023 12:37PM
Reported : 11/Oct/2023 02:05PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (CU	JE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	HAZY		CLEAR	Visual
pH	5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				; = 1 -
URINE PROTEIN	NEGATIVE	-	NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE	*	NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	POSITIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	POSITIVE +		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY			
PUS CELLS	6-8	/hpf	0-5	Microscopy
EPITHELIAL CELLS	3-4	/hpf	<10	MICROSCOPY
RBC	2-3	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

Page 12 of 13







: Mrs.SHOBA RANI S

Age/Gender

: 51 Y 6 M 26 D/F

UHID/MR No

: CJPN.0000088585

Visit ID

: CJPNOPV178763

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 9535046667

Collected

: 11/Oct/2023 08:31AM

Received

: 11/Oct/2023 12:37PM : 11/Oct/2023 02:05PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER FEMALE - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

DR.SHIVARAJA SHETTY M.B.B.S, M.D(Biochemistry) CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Md.Path.Pathologist Consultant Pathologist

Dr PRASANNA B.K.P

iinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 13 of 13



SIN No:UR2200181

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE